Sugi Predict

Sugi Predict / Compounds / SCHEMBL2523306

SCHEMBL2523306

SCHEMBL2523306

CCCCCOC[C@H](CO)OCCCCC

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.60
▸ LPAR1 Q92633 7/20 0.57
▸ LPAR3 Q9UBY5 7/20 0.57
▸ LPAR2 Q9HBW0 4/20 0.57
▸ ALDH1A1 P00352 1/20 0.56
▸ CNR1 P21554 1/20 0.56
▸ CNR2 P34972 1/20 0.56
▸ TLR2 O60603 2/20 0.49
▸ HTT P42858 2/20 0.48
▸ DNM1 Q05193 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ LPAR6 P43657 3/20 0.46
▸ LPAR4 Q99677 3/20 0.46
▸ LPAR5 Q9H1C0 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083230 1.00 USP2 (0.60) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL132573 1.00 USP2 (0.60) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL15016340 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL7058701 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL7063486 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL25266425 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL2417250 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL103054 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL10561321 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1
SCHEMBL7063456 0.98 USP2 (0.63) USP2LPAR1LPAR3LPAR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114344278-A Nucleic acid delivery vectors and uses thereof 南京吉迈生物技术有限公司 2022-04-15 — — CN claimed
CN-118221556-A Ionizable cationic lipid material, and preparation method and application thereof 南京吉迈生物技术有限公司 2024-06-21 — — CN disclosed
US-20240082154-A1 DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION CUORIPS INC. (JP) 2024-03-14 — — US disclosed
CN-115504945-A Ionizable heterocyclic lipid molecule and application thereof in preparation of lipid nanoparticles 南京吉迈生物技术有限公司 2022-12-23 — — CN disclosed
US-20210113464-A1 DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION CUORIPS INC. (JP) 2021-04-22 — — US disclosed
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES AG (AT) 2014-11-27 — — US disclosed
US-20140309186-A1 Metabolomics-Based Identification of Disease-Causing Agents GEORGIA TECH RESEARCH CORPORATION 2014-10-16 — — US disclosed
US-20110246081-A1 Metabolomics-Based Identification of Disease-Causing Agents GEORGIA TECH RESEARCH CORPORATION (US) 2011-10-06 — — US disclosed
US-20100323000-A1 METHOD AND PROCESS FOR PREPARING CARDIOLIPIN NEOPHARM, INC. (US) 2010-12-23 — — US disclosed
US-20080300418-A1 Synthesis of Cardiolipin Analogues and Uses Thereof AHMAD MOGHIS U 2008-12-04 — — US disclosed
WO-2005110379-A2 PULMONARY MALARIAL VACCINE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-11-24 — — WO disclosed
US-20050181037-A1 Cardiolipin compositions their methods of preparation and use NEOPHARM, INC. (US) 2005-08-18 — — US disclosed
EP-1021452-B1 PROCESS FOR SYNTHESIZING PHOSPHODIESTERS EPIX MEDICAL INC (US) 2003-04-02 — — EP disclosed
US-6376697-B1 Labelled phosphoinositides and analogues NUTRIMED BIOTECH 2002-04-23 — — US disclosed
US-5919967-A Process for synthesizing phosphodiesters EPIX MEDICAL, INC. (US) 1999-07-06 — — US disclosed
US-5438125-A For treating nervous system disorders NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1995-08-01 — — US disclosed
EP-0502827-A1 Sialic acid derivatives NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1992-09-09 — — EP disclosed
EP-0037582-B1 PROCESS FOR PREPARING 1,2-DIACYL-SN-GLYCEROLS KSV-Chemicals Oy (FI) 1983-10-05 — — EP disclosed
EP-0037582-A2 Process for preparing 1,2-diacyl-SN-glycerols KSV-Chemicals Oy (FI) 1981-10-14 — — EP disclosed
EP-0037582-A2 Process for preparing 1,2-diacyl-SN-glycerols KSV-Chemicals Oy (FI) 1981-10-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN TRPV1, ACHE, OPRL1 USP2 3233/4885LPAR1 107/4885LPAR3 38/4885
US-20210113464-A1 DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION PTGDR2, PLA2R1, PTGDR USP2 2253/4885LPAR1 8/4885LPAR3 24/4885
US-20050181037-A1 Cardiolipin compositions their methods of preparation and use LIPA, LCLAT1, PHOSPHO1 USP2 2382/4885LPAR1 62/4885LPAR3 61/4885
US-20080300418-A1 Synthesis of Cardiolipin Analogues and Uses Thereof PHOSPHO1, SGMS1, SGMS2 USP2 4646/4885LPAR1 96/4885LPAR3 102/4885
US-20240082154-A1 DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION LPAR2, PLA2R1, PTGDR2 USP2 1935/4885LPAR1 7/4885LPAR3 22/4885
US-20100323000-A1 METHOD AND PROCESS FOR PREPARING CARDIOLIPIN PHOSPHO1, SGMS1, SGMS2 USP2 3011/4885LPAR1 102/4885LPAR3 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.